HomeNew KRas Inhibitors

New KRas Inhibitors

Catalog No. Product Name Information
E6757 BBO-11818 BBO‑11818 is an orally active and non‑covalent inhibitor of pan‑KRAS that binds both the active (GTP‑bound, “ON”) and inactive (GDP‑bound, “OFF”) forms of multiple oncogenic KRAS mutants, including KRAS G12D and G12V. It potently suppresses MAPK signaling and viability in KRAS‑driven cell lines, induces tumor regressions in KRAS‑mutant xenograft models.
E6660 FMC-376 FMC-376 is a selective and irreversible dual inhibitor of both the ON and OFF states of KRASG12C. It binds covalently to the mutant cysteine at position 12 in KRAS G12C and directly blocks both the ON and OFF conformations of the mutant KRAS protein, leading to a complete and durable blockade of downstream signaling. FMC‑376 exhibits robust anti‑tumor activity in vivo.
E1577 AZD4747 AZD4747 is a selective, blood‑brain barrier‑permeable inhibitor of mutant GTPase KRASG12C, with the potential to treat KRAS^G12C‑positive tumors, including central nervous system (CNS) metastases.
E2540 Salvianolic acid F Salvianolic acid F acts as a KRAS inhibitor, with activity against KRAS G12D. It suppresses NF-kB, MMP-9, and NO production. In vitro studies show it reduces cancer cell proliferation, invasion, and migration while promoting apoptosis through the EP300/PI3K/AKT pathway. In vivo experiments demonstrate its inhibition of KRAS-dependent lung cancer cell growth via PI3K/AKT signaling. This compound has potential applications in studying multiple cancer types, particularly KRAS G12D-associated NSCLC and ovarian cancer.
E6643 SS-3091 SS‑3091 is a potent inhibitor of pan‑KRas that targets the interaction interfaces of KRas, destabilizing critical KRas–protein complexes and thereby blocking its downstream signaling pathways. SS‑3091 effectively inhibits KRas‑driven signaling in multiple cancer cell lines, including those harboring G12D, G12V, and G13D mutations, leading to reduced ERK and AKT phosphorylation.
≡ All KRas Inhibitors